PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2014 | 1 | 4 | 239-245
Article title

Terapie eksperymentalne w jaskrze

Content
Title variants
EN
Experimental therapies for glaucoma
Languages of publication
PL
Abstracts
EN
In a review on the basis of the present pathogenesis concept of glaucomatous optic neuropathy six elements of glaucoma future treatment strategy: baroprotection, vasoprotection, neuroprotection, gene therapy, regenerative medicine and immunotherapy, were described. Elements of pharmacogenomics in glaucoma and new drug delivery systems were also presented.
PL
W niniejszym artykule poglądowym omówiono, na podstawie aktualnej koncepcji patogenezy neuropatii jaskrowej, sześć kierunków przyszłej strategii terapii jaskry: baro-, wazo- i neuroprotekcję, terapię genową, medycynę regeneracyjną i immunoterapię. Przedstawiono także podstawy farmakogenomiki w jaskrze oraz nowe systemy transferu leków przeciwjaskrowych.
Discipline
Publisher
Journal
Year
Volume
1
Issue
4
Pages
239-245
Physical description
References
  • 1. Varma R, Lee PP, Goldberg I, et al. An assessment of the health and economic burden of glaucoma. Am J Ophthalmol 2011; 152: 515-522.
  • 2. Gupta N, Ang LC, Noël de Tilly L, et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 2006; 90: 674-678.
  • 3. Rao PV, Deng PF, Sasaki Y, et al. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility. Exp Eye Res 2005; 80: 197-206.
  • 4. Tian B, Kaufman PL. Effect of the Rho-kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res 2005; 80: 215-225.
  • 5. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest. Ophthalmol Vis Sci 2006; 47: 1991-1998.
  • 6. Zhang M, Rao PV. Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes. Invest Ophthalmol Vis Sci 2005; 46: 4130-4138.
  • 7. Njie YF, Kumar A, Qiao Z, et al. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest. Ophthalmol Vis Sci 2006; 47: 1999-2005.
  • 8. Villarreal G Jr, Chatterjee A, Oh SS, et al. Pharmacological regulation of SPARC by lovastatin in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2014; 55: 1657-1665.
  • 9. Strobbe E, Cellini M, Campos EC. Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study. Invest Ophthalmol Vis Sci 2013; 54: 968-973.
  • 10. von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 2014; 144: 41-49.
  • 11. Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. Am J Manag Care 2008; 14: S11-S14.
  • 12. Salt TE, Nizari S, Cordeiro MF, et al. Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma. Neurotox Res 2014; 26: 440-446.
  • 13. Kee C, Sohn S, Hwang JM. Stromelysin gene transfer into cultured human trabecular cells and rat trabecular meshwork in vivo. Invest Ophthalmol Vis Sci 2001; 42: 2856-2860.
  • 14. Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull 2004; 62: 473.
  • 15. Hudde T, Apitz J, Bordes-Alonso R, et al. Gene transfer to trabecular meshwork endothelium via direct injection into Schlemm’s canal and in vivo toxicity study. Curr Eye Res 2005; 30: 1051-1059.
  • 16. Angella GJ, Sherwood MB, Balasubramanian L, et al. Enhanced short-term plasmid transfection of filtration surgery tissues. Invest Ophthalmol Vis Sci 2000; 41: 4158-4162.
  • 17. Ulmer M, Li J, Yaspan BL, et al. Genome-wide analysis of central corneal thickness in primary open-angle glaucoma cases in the NEIGHBOR and GLAUGEN consortia. Invest Ophthalmol Vis Sci 2012; 53: 4468-4474.
  • 18. Chen LJ, Tam PO, Leung DY, et al. SNP rs1533428 at 2p16.3 as a marker for late-onset primary open-angle glaucoma. Mol Vis 2012; 18: 1629-1639.
  • 19. Nguyen CT, Vingrys AJ, Bui BV. Dietary ω-3 deficiency and IOP insult are additive risk factors for ganglion cell dysfunction. J Glaucoma 2013; 22: 269-277.
  • 20. Bull ND, Limb GA, Martin KR. Human Müller stem cell (MIO-M1) transplantation in a rat model of glaucoma: survival, differentiation, and integration. Invest Ophthalmol Vis Sci 2008; 49: 3449-3456.
  • 21. Bull ND, Irvine KA, Franklin RJ, et al. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 4244-4253.
  • 22. Jiang C, Moore MJ, Zhang X, et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 2007; 13: 1783-1792.
  • 23. Ellis-Behnke RG, Liang YX, You SW, et al. Nano neuro knitting: peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. Proc Natl Acad Sci USA 2006; 103: 5054-5059.
  • 24. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001; 19: 1141-1147.
  • 25. Kashiwagi K, Ito K, Haniuda H, et al. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci 2013; 54: 5629-5637.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-eb7ed859-5b66-43e0-a740-9c91e3ba687a
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.